DBV Technologies (NASDAQ:DBVT) Stock Passes Above Fifty Day Moving Average – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.75 and traded as high as $0.81. DBV Technologies shares last traded at $0.76, with a volume of 60,495 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DBVT. HC Wainwright increased their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. Finally, StockNews.com assumed coverage on DBV Technologies in a research report on Wednesday. They issued a “hold” rating for the company.

DBV Technologies Stock Down 2.1 %

The stock’s 50-day moving average price is $0.75 and its 200 day moving average price is $0.92. The company has a market cap of $73.73 million, a P/E ratio of -0.83 and a beta of 0.66.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.